KARPAS 929 Human Myeloma cell line, developed at the University of Cambridge, useful in oncology research.

Publications:

Karpas et al. (2005). Leuk. Lymphoma, 46(1), 101–112

Cambridge Enterprise Limited is the exclusive licensor for the Karpas cell line portfolio. We have partnered with ECACC (The European Collection of Cell Cultures; a Public Health England Culture Collection) to manage distribution of the majority of these cells on our behalf. Enquires to either organisation are welcomed.